Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of single- or double-dose AS03-adjuvanted H5N1 pandemic influenza vaccine in adults older than 60 years
2006-004041-42Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of H5N1 vaccine + AS03 in influenza (3 arms), sponsored by GSK. Primary endpoints: Humoral immune response to H5N1 vaccine, Neutralizing antibody response and 1 more. Started Oct 2006; status: completed.
02
Drugs
H5N1 vaccine + AS03
03
Conditions
influenza
Beyond the preview
Go deeper on 2006-004041-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004041-42.